TNNT2 and COVID-19: Levels of hs-cTnT in the convalescent phase, in contrast to levels during hospitalization, are associated with the presence of cardiac abnormalities, and very low concentrations (< 5 ng/L) seem to reliably rule out cardiac pathology after COVID-19, regardless of persistent dyspnea.